TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32068049

Group type: EXPERIMENTAL
Intervention: 5% sofpironium bromide gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% sofpironium bromide gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15% sofpironium bromide gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 32332634

Group type: EXPERIMENTAL
Intervention: Herbal medicine foot bath decoction (FBD) with ordinary dressing changes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with ordinary dressings
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with silver ion dressings
Number of subjects: 60
Study: 36306329

Group type: EXPERIMENTAL
Intervention: NETfacts health system (integrated model of Narrative Exposure Therapy and community-based intervention)
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Individual NET alone
Number of subjects: 1066
Study: 34930153

Group type: EXPERIMENTAL
Intervention: Astra‐Zeneca ChAdOx1 vaccine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pfizer BNT162b2 vaccine
Number of subjects: 50
Study: 32517117

Group type: EXPERIMENTAL
Intervention: Ideal avatar (IAC)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Real avatar (RAC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non avatar (NAC)
Number of subjects: 42
Study: 35318632

Group type: EXPERIMENTAL
Intervention: Multimedia insulin pen-injector health education intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (standard education)
Number of subjects: 72
Study: 32741502

Group type: EXPERIMENTAL
Intervention: Oxytocin 40-IU administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions
Number of subjects: 48
Study: 34101252

Group type: EXPERIMENTAL
Intervention: Intensive nutrition treatment (INT) with protein intake of 1.70 ± 0.21 g/kg/d
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard nutrition treatment (SNT) with protein intake of 1.06 ± 0.21 g/kg/d
Number of subjects: 41
Study: 34872511

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days plus standard of care (SOC) treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment alone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 105
Study: 34714508

Group type: EXPERIMENTAL
Intervention: Multi-component community intervention including social marketing targeting adolescents and parents, and community intervention to reduce underage alcohol sales.
Number of subjects: 3377

Group type: EXPERIMENTAL
Intervention: Exposure to social marketing
Number of subjects: 3377

Group type: EXPERIMENTAL
Intervention: Multi-component community intervention
Number of subjects: 3377

Group type: EXPERIMENTAL
Intervention: Parents setting a rule
Number of subjects: 3377

Group type: EXPERIMENTAL
Intervention: Total indirect effects from the intervention
Number of subjects: 3377

Group type: EXPERIMENTAL
Intervention: Parents not supplying alcohol
Number of subjects: 3377
Study: 33155057

Group type: EXPERIMENTAL
Intervention: Green light-emitting diodes (GLED) for 1 to 2 hours daily for 10 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: White light-emitting diodes
Number of subjects: 21
Study: 36395875

Group type: EXPERIMENTAL
Intervention: Aspirin plus ticagrelor (AT group)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel (AC group)
Number of subjects: 278
Study: 36405056

Group type: EXPERIMENTAL
Intervention: Date palm pollen (DPP) supplementation (300 mg per day for 35 days)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (starch capsule)
Number of subjects: 68
Study: 32966810

Group type: EXPERIMENTAL
Intervention: Surufatinib (300 mg, orally once per day)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Surufatinib
Number of subjects: 172
Study: 33205673

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) at a fixed dose of 25 mg/m2/day
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) escalation (up to 50 or 75 mg/m2/day)
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX), asparaginase, and vincristine
Number of subjects: 952
Study: 35811477

Group type: EXPERIMENTAL
Intervention: 12-weeks exercise-based cardiac rehabilitation including a psycho-educational programme
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study: 34183256

Group type: EXPERIMENTAL
Intervention: Experimental group (new approach to secure PVC with surgical knot and elastic adhesive bandage)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (standard approach using sterile, transparent, and protective film)
Number of subjects: 248
Study: 35849787

Group type: EXPERIMENTAL
Intervention: High-flow oxygen
Number of subjects: 494

Group type: COMPARATOR
Intervention: VenturiMask oxygen
Number of subjects: 494
Study: 32449010

Group type: EXPERIMENTAL
Intervention: Accelerated deep transcranial magnetic stimulation (adTMS) for 10 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Accelerated deep transcranial magnetic stimulation (adTMS) for 15 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: adTMS (both protocols)
Number of subjects: 28
Study: 32507128

Group type: EXPERIMENTAL
Intervention: Oxycodone PR tablet with naltrexone (T+)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oxycodone PR tablet without naltrexone (T)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxygesic PR tablet with naltrexone (R+)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oxygesic PR tablet without naltrexone (R)
Number of subjects: 24
Study: 616173046

Group type: EXPERIMENTAL
Intervention: Digoxin (D, 0.25 mg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Ivabradine (I, 15 mg)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (non-receiving both drugs)
Number of subjects: 165
Study: 36001052

Group type: EXPERIMENTAL
Intervention: MyJourney online self-guided psychosocial intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 235
Study: 32840169

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-affirmation control
Number of subjects: 0
Study: 32740086

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing factor (CRF) 100 μg
Number of subjects: 21

Group type: COMPARATOR
Intervention: 5-mL saline solution (placebo)
Number of subjects: 21
Study: 35073958

Group type: EXPERIMENTAL
Intervention: HVOPM+NOx
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HVONOx
Number of subjects: 19

Group type: COMPARATOR
Intervention: FA
Number of subjects: 19
Study: 34420346

Group type: EXPERIMENTAL
Intervention: First method based on Hankel matrices; provides a family of entanglement criteria; lowest order reduces to p_{3}-positive-partial-transpose criterion.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second method; optimal entanglement detection method.
Number of subjects: 0
Study: 32682929

Group type: EXPERIMENTAL
Intervention: 1 g of vitamin C daily for 30 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.2 g of NAC daily for 30 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 g of vitamin C
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.2 g of NAC
Number of subjects: 36

Group type: COMPARATOR
Intervention: 1 g of vitamin C and 1.2 g of NAC
Number of subjects: 36
Study: 35413719

Group type: EXPERIMENTAL
Intervention: DHA supplementation (1.2 g daily)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study: 34089564

Group type: EXPERIMENTAL
Intervention: Microdermabrasion (MDA) combined with glycolic acid 70% (GA70%) peel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glycolic acid 70% (GA70%) alone
Number of subjects: 30
Study: 35906473

Group type: EXPERIMENTAL
Intervention: Inulin supplementation (13 g of extracted inulin powder from Thai Jerusalem artichoke)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Isocaloric maltodextrin
Number of subjects: 155

Group type: COMPARATOR
Intervention: Dietary fiber advice
Number of subjects: 155
Study: 34628384

Group type: EXPERIMENTAL
Intervention: Hypoxic training (main group, 29 patients)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Simulated training (control group, 18 patients)
Number of subjects: 47
Study: 32631414

Group type: EXPERIMENTAL
Intervention: Individualized PEEP (iPEEP) determined by Cstat-directed PEEP titration
Number of subjects: 80

Group type: COMPARATOR
Intervention: PEEP of 5 cmH2O (PEEP5 group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Standard lung-protective ventilation methods (low tidal volumes, fraction of inspired oxygen ≥ 0.5, recruitment maneuvers)
Number of subjects: 80
Study: 35241937

Group type: EXPERIMENTAL
Intervention: Breathing Exercises, Foot Reflexology, and Massage (BRM)
Number of subjects: 225
Study: 33346674

Group type: EXPERIMENTAL
Intervention: Healing Hearts Together (HHT) intervention
Number of subjects: 78
Study: 34655014

Group type: EXPERIMENTAL
Intervention: High-volume group received 3600 mL of lactated Ringer's solution (LRS) in 24 hours starting 2 hours before the ERCP.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group received maintenance fluid hydration calculated by the Holliday-Segar method.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-volume group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 33077680

Group type: EXPERIMENTAL
Intervention: Intravenous t-PA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: DAPT
Number of subjects: 0
Study: 32347139

Group type: EXPERIMENTAL
Intervention: Standard FEC chemotherapy (600/60/600 mg/m2)
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced leukopenia
Number of subjects: 1452
Study: 34783687

Group type: EXPERIMENTAL
Intervention: Neighborhood violent crime victimization (objective and subjective measures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptions of community well-being and support
Number of subjects: 0
Study: 34867514

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 40 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Psychological Intervention (PI) for 40 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comprehensive Intervention (CI) for 40 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 35025757

Group type: EXPERIMENTAL
Intervention: 0.2% Hyaluronic Acid cream
Number of subjects: 168

Group type: COMPARATOR
Intervention: Neutral comparator cream (identical cream without HA)
Number of subjects: 168
Study: 32552711

Group type: EXPERIMENTAL
Intervention: Modular stem (50 ABG II stems with modular necks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard stem (25 standard stems)
Number of subjects: 75
Study: 35363058

Group type: EXPERIMENTAL
Intervention: Mindful Walking Program (MWP) - eight weekly sessions
Number of subjects: 55

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 55
Study: 34486320

Group type: EXPERIMENTAL
Intervention: Growing media composition of 25% soil, 25% rice husk charcoal, 50% organic plus fertilizer (M5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growing media compositions of 50% soil, 0% rice husk charcoal, 50% organic plus fertilizer (M2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growing media compositions of 50% soil, 50% rice husk charcoal, 25% organic plus fertilizer (M4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growing media compositions of 25% soil, 50% rice husk charcoal, 25% organic plus fertilizer (M7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growing media compositions of 0% soil, 50% rice husk charcoal, 50% organic plus fertilizer (M8)
Number of subjects: 0
Study: 34817440

Group type: EXPERIMENTAL
Intervention: Thin-wire snare (0.30 mm)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Thick-wire snare (0.47 mm)
Number of subjects: 660
Study: 32052516

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA) 10 mg + Saxagliptin (SAXA) 5 mg
Number of subjects: 444

Group type: COMPARATOR
Intervention: Glimepiride (GLIM) 1-6 mg (titrated)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA) + Saxagliptin (SAXA)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Glimepiride (GLIM)
Number of subjects: 444
Study: 35877601

Group type: EXPERIMENTAL
Intervention: Bedaquiline (TB drug)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Pretomanid (TB drug)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Dolutegravir (HIV drug)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Doravirine (HIV drug)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (HCV drug)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (HCV drug)
Number of subjects: 380

Group type: COMPARATOR
Intervention: TB drugs (Bedaquiline and Pretomanid)
Number of subjects: 380
Study: 33978188

Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg/d) for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 100
Study: 33120822

Group type: EXPERIMENTAL
Intervention: Moxibustion combined with characteristic lifestyle intervention of TCM
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Moxibustion combined with lifestyle intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lifestyle intervention only
Number of subjects: 150
Study: 35634651

Group type: EXPERIMENTAL
Intervention: Condition representing mental illness across the warmth-competence stereotype space
Number of subjects: 60

Group type: COMPARATOR
Intervention: Generic measures of discrimination (e.g., social distance scales)
Number of subjects: 60
Study: 32841326

Group type: EXPERIMENTAL
Intervention: NAFLD-related genetic risk score (GRS)
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: PNPLA3 rs738409
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: 2-sample MR
Number of subjects: 904
Study: 32851419

Group type: EXPERIMENTAL
Intervention: Baseline serum 25(OH)D concentration
Number of subjects: 341484

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency or deficiency
Number of subjects: 341484
Study: 34165010

Group type: EXPERIMENTAL
Intervention: Patients with 25OHD <20 ng/ml
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Patients with 25OHD <10 ng/ml
Number of subjects: 549
Study: 32544161

Group type: EXPERIMENTAL
Intervention: Two-way texting (2wT) intervention
Number of subjects: 362
Study: 35720026

Group type: EXPERIMENTAL
Intervention: Hospital-family rehabilitation intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine intervention (Control)
Number of subjects: 100
Study: 33146457

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Exercise (30 minutes of interval training 5 days per week)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (habitual living)
Number of subjects: 120
Study: 35436974

Group type: EXPERIMENTAL
Intervention: WalkingPad app with built-in virtual assistant (Experimental group 2)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: WalkingPad app without built-in virtual assistant (Experimental group 1)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Practice diary (Active control group)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 300
Study: 34107861

Group type: EXPERIMENTAL
Intervention: Gui‐fu‐di‐huang‐wan (GFDHW) treatment and lifestyle intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GFDHW treatment and lifestyle intervention
Number of subjects: 60
Study: 34360425

Group type: EXPERIMENTAL
Intervention: Beta-Alanine (6.4 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both B-ALA and Placebo
Number of subjects: 20
Study: 32978471

Group type: EXPERIMENTAL
Intervention: Incentivized experiments (monetary payments to elicit norms)
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Self-report scales
Number of subjects: 1656
Study: 36205739

Group type: EXPERIMENTAL
Intervention: TAC-302 200 mg twice daily for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 32396474

Group type: EXPERIMENTAL
Intervention: HIV disclosure status (Yes/No)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Patterns of disclosure (Broad, Selective, Nondisclosure)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Factors predicting HIV disclosure
Number of subjects: 371
Study: 34978388

Group type: EXPERIMENTAL
Intervention: Generic roxatidine acetate hydrochloride (RAH) sustained-release capsule, 75 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Commercial capsule (ALTAT)
Number of subjects: 72
Study: 32703124

Group type: EXPERIMENTAL
Intervention: Preference-based designs (two-stage, fully randomised, and partially randomised)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional trials
Number of subjects: 0
Study: 35373306

Group type: EXPERIMENTAL
Intervention: Improved mental healthcare (MHC)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Integrated interventions (INT)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 666
Study: 32604921

Group type: EXPERIMENTAL
Intervention: PD-fluid supplemented with 8 mM alanyl-glutamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (PD-fluid without alanyl-glutamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FTIR spectroscopy
Number of subjects: 0
Study: 33560875

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 33189426

Group type: EXPERIMENTAL
Intervention: Combined intervention (SNA+VHS)
Number of subjects: 34633

Group type: EXPERIMENTAL
Intervention: Social norm‐based motivational intervention (SNA)
Number of subjects: 34633

Group type: EXPERIMENTAL
Intervention: Implementation intention‐based Volitional Help Sheet (VHS)
Number of subjects: 34633

Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 34633
Study: 32950590

Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 32683828

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision with preservation of Denonvilliers' fascia (iTME)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional total mesorectal excision (TME)
Number of subjects: 0
Study: 36506468

Group type: EXPERIMENTAL
Intervention: Early-start group (aspirin 100 mg daily starting 3 days after operation)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Normal-start group (no antithrombotic therapy until 30 days after operation)
Number of subjects: 250
Study: 32606057

Group type: EXPERIMENTAL
Intervention: Elastic-band resistance exercise with HMB supplementation
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Vibration treatment with HMB supplementation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144
Study: 34983251

Group type: EXPERIMENTAL
Intervention: AIM HI therapist training for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (observation of routine care)
Number of subjects: 0
Study: 34422323

Group type: EXPERIMENTAL
Intervention: Fructose (75 grams added to diet for 14 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucose (75 grams added to diet for 14 days)
Number of subjects: 10
Study: 34146511

Group type: EXPERIMENTAL
Intervention: Efgartigimod (10 mg/kg), administered as four infusions per cycle (one infusion per week), repeated as needed depending on clinical response no sooner than 8 weeks after initiation of the previous cycle.
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo, administered as matching infusions.
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Efgartigimod
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 33765453

Group type: EXPERIMENTAL
Intervention: Health systems intervention (three-phase intervention: LTBI programme evaluation, local decision making, and strengthening activities)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (standard LTBI care)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Health systems intervention
Number of subjects: 24
Study: 33326694

Group type: COMPARATOR
Intervention: teriparatide (20 μg/day, daily subcutaneous injection for 6 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: combined treatment of WJ‐MSCs (intramedullary [4 × 107 cells] injection and intravenous [2 × 108 cells] injection after 1 week) and teriparatide (20 μg/day, daily subcutaneous injection for 6 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: teriparatide alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: combined treatment of WJ‐MSCs and teriparatide
Number of subjects: 20
Study: 34429151

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Attention-matched control
Number of subjects: 51
Study: 32229173

Group type: EXPERIMENTAL
Intervention: Haemodynamic optimisation using photoplethysmography (interventional group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intermittent mean arterial pressure (control group)
Number of subjects: 160
Study: 35504197

Group type: EXPERIMENTAL
Intervention: Porous metaphyseal cones 3D‐printed of titanium
Number of subjects: 0
Study: 33766533

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT) or supraclavicular radiation therapy (SCV RT)
Number of subjects: 185

Group type: COMPARATOR
Intervention: No PMRT or SCV RT
Number of subjects: 185
Study: 35462880

Group type: EXPERIMENTAL
Intervention: Complete nutrition drink with retrograded starch
Number of subjects: 18
Study: 32753064

Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch 130/0.4 (colloid group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (crystalloid group)
Number of subjects: 60